The U.S. Department of Health and Human Services (HHS) recently announced two major initiatives to shed light on long COVID, a condition affecting millions. First, the agency plans to establish the Office of Long COVID Research and Practice. HHS is also set to launch new long COVID-19 clinical trials through its RECOVER initiative. Jointly, the…
WuXi STA expands peptide manufacturing capacity to meet global demand
WuXi STA, a prominent global contract research, development and manufacturing organization (CRDMO), has increased its peptide manufacturing output at its Changzhou campus. Located in southern Jiangsu province in China, Changzhou is part of the Yangtze River Delta region, which is among the most economically developed areas in the country. WuXi STA’s expansion includes two additional…
Biotech industry downturn: Struggles continue as layoffs mount and funding dwindles
The once-thriving biotech industry, known for breakthroughs in cell therapy, gene editing, and messenger RNA, is now showing signs of a downturn. During the early days of the pandemic, mRNA vaccine trailblazers like Moderna (Nasdaq:MRNA), Pfizer (NYSE:PFE), and BioNTech (Nasdaq:BNTX) enjoyed skyrocketing revenues, but the recent biotech industry downturn has cast a shadow over this…
Nanoform and Boehringer Ingelheim execute master services agreement
Nanoparticle medicine specialist Nanoform (Helsinki, Finland) and Boehringer Ingelheim (Ingelheim am Rhein, Germany) will collaborate on proof-of-concept studies related to Nanoform’s CESS technology. The master services agreement enables the two parties to move forward with pre-clinical research related to CESS, an acronym for “Controlled Expansion of Supercritical Solutions.” CESS has the potential to optimize the…